M. Zheng

发表

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

E. Winer, H. Rugo, P. LoRusso, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to W. Wick et al

T. Mikkelsen, W. Yung, M. Prados, 2010 .

Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

P. LoRusso, L. Amler, H. Burris, 2010 .

A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.

H. Rugo, P. LoRusso, L. Amler, 2009 .

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

T. Mikkelsen, W. Yung, M. Prados, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

H. Rugo, L. Amler, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

T. Mikkelsen, W. Yung, M. Prados, 2011, Neuro-oncology.

Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)

N. Wolmark, S. Loibl, M. Untch, 2013 .

Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.

YounJeong Choi, R. Sane, M. Hilton, 2023, Journal of biopharmaceutical statistics.

799P Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial

Y. Huang, J. Li, W. Wei, 2021, Annals of Oncology.

8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study

T. Cloughesy, H. Friedman, A. Das, 2009 .

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

T. Mikkelsen, M. Prados, P. Wen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

T. Mikkelsen, M. Prados, P. Wen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.